Updates from Marinus on Ganaxolone Trials for 3 Forms of Epilepsy

Marinus Pharmaceuticals has recently announced updates on its ganaxolone programs for tuberous sclerosis complex (TSC), PCDH19-related epilepsy (PCDH19-RE), and CDKL5 deficiency disorder (CDD). Ganaxolone Ganaxolone is a positive allosteric modulator…

Continue Reading Updates from Marinus on Ganaxolone Trials for 3 Forms of Epilepsy
Ganaxolone Being Investigated as Treatment for Tuberous Sclerosis and CDKL5 Deficiency Disorder
source: pixabay.com

Ganaxolone Being Investigated as Treatment for Tuberous Sclerosis and CDKL5 Deficiency Disorder

Marinus Pharmaceuticals is a pharmaceutical company that works to create treatments for epilepsy and other neuropsychiatric disorders. They are in the process of conducting clinical trials to evaluate the safety…

Continue Reading Ganaxolone Being Investigated as Treatment for Tuberous Sclerosis and CDKL5 Deficiency Disorder

Rare Epilepsy Updates:  One New Drug, Two Clinical Trials, and Orphan Drug Designation

  A recent article published in Globe Newswire heralded Marinus Pharmaceuticals’ new drug, ganaxolone. The drug has been studied in over 1600 patients and is now being tested in two clinical…

Continue Reading Rare Epilepsy Updates:  One New Drug, Two Clinical Trials, and Orphan Drug Designation
Initial Trial Data Looks Promising for a Potential Treatment for Rare Epilepsies
geralt / Pixabay

Initial Trial Data Looks Promising for a Potential Treatment for Rare Epilepsies

According to a story from sectorpublishingintelligence.co.uk, the drug company Ovid Therapeutics Inc. has recently announced that the early data from its phase 2 clinical trial is mostly encouraging. This clinical…

Continue Reading Initial Trial Data Looks Promising for a Potential Treatment for Rare Epilepsies

Gene Therapy for 12 Rare Diseases will be Investigated Thanks to this Industry-Academia Partnership

Extended Collaboration  Amicus Therapeutics has just announced that they are expanding their collaboration with the University of Pennsylvania's Perelman School of Medicine for the next five years. This collaboration is…

Continue Reading Gene Therapy for 12 Rare Diseases will be Investigated Thanks to this Industry-Academia Partnership
Ganaxolone Shows Potential in Treating CDKL5 and Reveals Biomarker in PCDH19 Epilepsy
stevepb / Pixabay

Ganaxolone Shows Potential in Treating CDKL5 and Reveals Biomarker in PCDH19 Epilepsy

According to a story from globenewswire.com, the biopharmaceutical company Marinus Pharmaceuticals, Inc., recently announced the presentation of Phase 2 clinical trial of the drug ganaxolone as a treatment for CDKL5…

Continue Reading Ganaxolone Shows Potential in Treating CDKL5 and Reveals Biomarker in PCDH19 Epilepsy

Two Phase 2 Clinical Studies of a Drug for Rare Epilepsies Have Been Initiated

Two Phase 2 clinical trials called ‘Elektra’ and ‘Arcade’ have been initiated. They will investigate the drug OV935/TAK-935 as a potential treatment for paediatric patients with rare epilepsies. For more…

Continue Reading Two Phase 2 Clinical Studies of a Drug for Rare Epilepsies Have Been Initiated
Takeda and Ovid Have Provided an Update on the Clinical Development Program for an Investigational Anti-Epileptic Drug
stevepb / Pixabay

Takeda and Ovid Have Provided an Update on the Clinical Development Program for an Investigational Anti-Epileptic Drug

  Takeda Pharmaceutical Company Limited and Ovid Therapeutics have released an overview of the clinical development program for TAK-935/OV935, an investigational drug that is being developed as a potential anti-epileptic…

Continue Reading Takeda and Ovid Have Provided an Update on the Clinical Development Program for an Investigational Anti-Epileptic Drug
Three Planned Studies of an Experimental Drug to Treat Rare Epilepsies Have Been Announced
kkolosov / Pixabay

Three Planned Studies of an Experimental Drug to Treat Rare Epilepsies Have Been Announced

The organisations Takeda Pharmaceutical Company and Ovid Therapeutics are collaborating over the development of the experimental drug TAK-935/OV935 as a possible treatment for several rare epilepsy syndromes. Takeda has just…

Continue Reading Three Planned Studies of an Experimental Drug to Treat Rare Epilepsies Have Been Announced
The Orphan Disease Center Just Announced Their 2018 Grant For CDKL5 Deficiency Disorder
source: pixabay.com

The Orphan Disease Center Just Announced Their 2018 Grant For CDKL5 Deficiency Disorder

The Orphan Disease Center in association with the University of Pennsylvania and the Loulou Foundation just announced their 2018 Pilot Grant Program for CDKL5 Deficiency Disorder. CDKL5 deficiency disorder (CDD)…

Continue Reading The Orphan Disease Center Just Announced Their 2018 Grant For CDKL5 Deficiency Disorder
Close Menu